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Impaired cognition fundamentally impact that primarily affects the ability to function in the
workplace, at school, or at home. Also, disrupted cognition may prevent severely ill patients
from deriving full benefit from psychological treatments. The evidence suggests marked
cognitive impairment predicts poor response to antidepressant medication, independent of
symptom severity. Among depressed patients, cognitive abnormalities may not resolve
completely upon remission, and are also observed in first-degree relatives, suggesting that
they may be trait markers (predisposing factors).
Cognitive deficits in schizophrenia are pervasive, severe, and largely independent of the
positive and negative symptoms of the illness. Current schizophrenia treatment has been
limited in addressing the cognitive deficits of the illness. Although patients with psychotic
mood disorders may present with a similar pattern of deficits, the magnitude of the deficits in
schizophrenia is substantially greater. Cognitive performance in schizophrenia appears to be
stable across fluctuations in illness symptoms, while deficits in affective disorders are more
closely tied to clinical state. Cognitive deficits in schizophrenia are significantly correlated
with functional outcome with regards to employment, independent living, community
functioning, and social functioning. This presentation summarizes the assessment, and
treatment of negative and cognitive symptoms in patients with schizophrenia and in
depressive disorders, including pharmacologic and nonpharmacological therapies that can
be used in clinical care now, as well as pharmacologic approaches that are being tested.

